What does the future hold for ctDNA testing in lung cancer?

Sanjay Popat, MBBS, FRCP, PhD, Royal Marsden Hospital, London, UK, emphasizes the need to optimize the process of circulating tumor DNA (ctDNA) testing in lung cancer diagnosis, citing bandwidth and manpower constraints as significant challenges. Embedding ctDNA testing into routine hospital systems will allow for early testing at the time of patient presentation, and reduce unnecessary repeat testing of tissue samples. Educating the workforce on interpreting complex genetic reports will be important for the successful implementation of ctDNA testing in clinical practice. This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.